These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 34108576)

  • 1. Clinical significance of tacrolimus intra-patient variability on kidney transplant outcomes according to pre-transplant immunological risk.
    Kim EJ; Kim SJ; Huh KH; Kim BS; Kim MS; Kim SI; Kim YS; Lee J
    Sci Rep; 2021 Jun; 11(1):12114. PubMed ID: 34108576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late intra-patient tacrolimus trough level variability as a major problem in kidney transplantation: A Collaborative Transplant Study Report.
    Süsal C; Döhler B
    Am J Transplant; 2019 Oct; 19(10):2805-2813. PubMed ID: 30859672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients.
    Vanhove T; Vermeulen T; Annaert P; Lerut E; Kuypers DRJ
    Am J Transplant; 2016 Oct; 16(10):2954-2963. PubMed ID: 27013142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients.
    Seibert SR; Schladt DP; Wu B; Guan W; Dorr C; Remmel RP; Matas AJ; Mannon RB; Israni AK; Oetting WS; Jacobson PA
    Clin Transplant; 2018 Dec; 32(12):e13424. PubMed ID: 30318646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled trial assessing the impact of everolimus and low-exposure tacrolimus on graft outcomes in kidney transplant recipients.
    Taber DJ; Chokkalingam A; Su Z; Self S; Miller D; Srinivas T
    Clin Transplant; 2019 Oct; 33(10):e13679. PubMed ID: 31365151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Number of Episodes of Subtherapeutic Tacrolimus Blood Level Is Independently Associated With Reduced Kidney Graft Survival.
    Meisel E; Bielopolski D; Steinmetz T; Agur T; Lichtenberg S; Goldman S; Herman-Edelstein M; Nesher E; Rahamimov R; Rozen-Zvi B
    Clin Transplant; 2024 Sep; 38(9):e15460. PubMed ID: 39302223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study.
    Gatault P; Kamar N; Büchler M; Colosio C; Bertrand D; Durrbach A; Albano L; Rivalan J; Le Meur Y; Essig M; Bouvier N; Legendre C; Moulin B; Heng AE; Weestel PF; Sayegh J; Charpentier B; Rostaing L; Thervet E; Lebranchu Y
    Am J Transplant; 2017 May; 17(5):1370-1379. PubMed ID: 27862923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrolimus intrapatient variability in BK virus nephropathy and chronic calcineurin toxicity in kidney transplantation.
    Turgut D; Sayin B; Soy EA; Topcu Dİ; Ozdemir BH; Haberal M
    Saudi J Kidney Dis Transpl; 2021; 32(2):348-354. PubMed ID: 35017328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in the commercial brand of tacrolimus lead to subtherapeutic trough levels and acute rejection in renal transplant recipients.
    Arreola-Guerra JM; Alberú J; Chew-Wong A; Macias DM; Hernández-Rosales J; Zuñiga-Macías L; Delgadillo-Castañeda R; Ricalde-Ríos G; Haro-Alcalde F; Villafán-Bernal JR; Ramos-Medellín CL; Reyes-Acevedo R
    Clin Transplant; 2019 Dec; 33(12):e13749. PubMed ID: 31691354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long-Term Stable Kidney Transplant Recipients.
    Dugast E; Soulillou JP; Foucher Y; Papuchon E; Guerif P; Paul C; Riochet D; Chesneau M; Cesbron A; Renaudin K; Dantal J; Giral M; Brouard S
    Am J Transplant; 2016 Nov; 16(11):3255-3261. PubMed ID: 27367750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protocol-based nurse coordinator management of ambulatory tacrolimus dosing in de novo renal transplant recipients-A single-center experience with a large African American population.
    Elmaasarani Z; Mardis C; Gylten L; Taber DJ; Fleming J; Patel N; Baliga P; Rao V; Rohan V; DuBay D; Pilch NA
    Clin Transplant; 2019 Oct; 33(10):e13701. PubMed ID: 31461791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study.
    Harland RC; Klintmalm G; Jensik S; Yang H; Bromberg J; Holman J; Kumar MSA; Santos V; Larson TJ; Wang X
    Am J Transplant; 2020 Jan; 20(1):159-171. PubMed ID: 31509331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Belatacept in renal transplant recipient with mild immunologic risk factor: A pilot prospective study (BELACOR).
    Leibler C; Matignon M; Moktefi A; Samson C; Zarour A; Malard S; Boutin E; Pilon C; Salomon L; Natella PA; Durrbach A; Robert T; Canoui-Poitrine F; Grimbert P
    Am J Transplant; 2019 Mar; 19(3):894-906. PubMed ID: 30582270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tacrolimus exposure in the real world: an analysis from the Mycophenolic acid Observational REnal transplant study.
    Shihab FS; Olyaei A; Wiland A; McCague K; Norman DJ
    Clin Transplant; 2014 Jul; 28(7):768-75. PubMed ID: 24754603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The TOMATO Study (Tacrolimus Metabolization in Kidney Transplantation): Impact of the Concentration-Dose Ratio on Death-censored Graft Survival.
    Jouve T; Fonrose X; Noble J; Janbon B; Fiard G; Malvezzi P; Stanke-Labesque F; Rostaing L
    Transplantation; 2020 Jun; 104(6):1263-1271. PubMed ID: 31415035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early post-transplant conversion from tacrolimus to belatacept for prolonged delayed graft function improves renal function in kidney transplant recipients.
    Wojciechowski D; Chandran S; Vincenti F
    Clin Transplant; 2017 May; 31(5):. PubMed ID: 28190259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten-year observational follow-up of a randomized trial comparing cyclosporine and tacrolimus therapy combined with steroid withdrawal in living-donor renal transplantation.
    Kim J; Park J; Hwang S; Yoo H; Kim K; Park JB; Jang HR; Lee JE; Kim SJ; Kim YG; Kim DJ; Oh HY; Huh W
    Clin Transplant; 2018 Sep; 32(9):e13372. PubMed ID: 30080284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tacrolimus Intrapatient Variability on Graft Outcomes in Adherent Renal Transplantation Patients: A Cross-Sectional Study.
    Nafar M; Keshtkari S; Ziaie S; Firouzan A; Borumandnia N; Dalili N; Poorrezagholi F; Samadian F; Samavat S
    Iran J Kidney Dis; 2024 May; 18(3):187-194. PubMed ID: 38904339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prednisone-free maintenance immunosuppression in obese kidney transplant recipients.
    Matas AJ; Vock DM
    Clin Transplant; 2019 Oct; 33(10):e13668. PubMed ID: 31310030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation.
    Davis S; Gralla J; Klem P; Tong S; Wedermyer G; Freed B; Wiseman A; Cooper JE
    Am J Transplant; 2018 Apr; 18(4):907-915. PubMed ID: 28925597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.